Background-In the vascular system, elevated levels of reactive oxygen species (ROS) produce oxidative stress and predispose to the development of atherosclerosis. Therefore, it is important to understand the systems producing and those scavenging vascular ROS. Here, we analyzed the ROS-reducing capability of paraoxonase-2 (PON2) in different vascular cells and its involvement in the endoplasmic reticulum stress pathway known as the unfolded protein response. Methods and Results-Quantitative real-time polymerase chain reaction and Western blotting revealed that PON2 is equally expressed in vascular cells and appears in 2 distinct glycosylated isoforms. By determining intracellular ROS, we show that overexpression of PON2 markedly reduced ROS, whereas its knockdown increased ROS levels significantly. Using microscopic and biochemical methods, we found PON2 mainly in the nuclear membrane and endoplasmic reticulum. Furthermore, PON2 expression was induced at both the promoter and protein levels by endoplasmic reticulum stress pathway unfolded protein response. This pathway may promote both apoptotic and survival mechanisms. Functionally, PON2 reduced unfolded protein response-accompanying oxidative stress and unfolded protein response-derived caspase activation. Conclusion-We suggest that PON2 represents an endogenous defense mechanism against vascular oxidative stress and unfolded protein response-induced cell death, thereby contributing to the prevention of atherosclerosis. (Circulation.

Major contributors to atherosclerosis are oxidative damage and endoplasmic reticulum (ER) stress-induced apoptosis; both of which can be diminished by the anti-oxidative protein paraoxonase-2 (PON2). ER stress is also relevant to cancer and associated with anti-cancer treatment resistance. Hence, we addressed, for the first time, whether PON2 contributes to tumorigenesis and apoptotic escape. Intriguingly, we found that several human tumors upregulated PON2 and such overexpression provided resistance to different chemotherapeutics (imatinib, doxorubicine, staurosporine, or actinomycin) in cell culture models. This was reversed after PON2 knock-down. Remarkably, just deficiency of PON2 caused apoptosis of selective tumor cells per se, demonstrating a previously unanticipated oncogenic function. We found a dual mechanistic role. During ER stress, high PON2 levels lowered redox-triggered induction of pro-apoptotic CHOP particularly via the JNK pathway, which prevented mitochondrial cell death signaling. Apart from CHOP, PON2 also diminished intrinsic apoptosis as it prevented mitochondrial superoxide formation, cardiolipin peroxidation, cytochrome c release, and caspase activation. Ligand-stimulated apoptosis by TRAIL or TNFα remained unchanged. Finally, PON2 knock-down caused vast reactive oxygen species formation and stimulated JNK-triggered CHOP expression, but inhibition of JNK signaling did not prevent cell death, demonstrating the pleiotropic, dominating anti-oxidative effect of PON2. Therefore, targeting redox balance is powerful to induce selective tumor cell death and proposes PON2 as new putative anti-tumor candidate.

To achieve malignancy, cancer cells convert numerous signaling pathways, with evasion from cell death being a characteristic hallmark. The cell death machinery represents an anti-cancer target demanding constant identification of tumor-specific signaling molecules. Control of mitochondrial radical formation, particularly superoxide interconnects cell death signals with appropriate mechanistic execution. Superoxide is potentially damaging, but also triggers mitochondrial cytochrome c release. While paraoxonase (PON) enzymes are known to protect against cardiovascular diseases, recent data revealed that PON2 attenuated mitochondrial radical formation and execution of cell death. Another family member, PON3, is poorly investigated. Using various cell culture systems and knockout mice, here we addressed its potential role in cancer. PON3 is found overexpressed in various human tumors and diminishes mitochondrial superoxide formation. It directly interacts with coenzyme Q10 and presumably acts by sequestering ubisemiquinone, leading to enhanced cell death resistance. Localized to the endoplasmic reticulum (ER) and mitochondria, PON3 abrogates apoptosis in response to DNA damage or intrinsic but not extrinsic stimulation. Moreover, PON3 impaired ER stress-induced apoptotic MAPK signaling and CHOP induction. Therefore, our study reveals the mechanism underlying PON3's anti-oxidative effect and demonstrates a previously unanticipated function in tumor cell development. We suggest PONs represent a novel class of enzymes crucially controlling mitochondrial radical generation and cell death. Cancer is one of the most life-threatening diseases and will remain a demanding issue in healthcare given the increase in life expectancy, constantly growing population and incidence of risk-factor acquiring patients. It is well established that several cellular deregulations are required for durable malignant transformation. Among them are sustained proliferation, replicative immortality, evasion of immune destruction and escape from cell death.1 Thus, tumor cells represent complex, broadly re-organized entities such that effective therapies demand tumor-specific identification of underlying mechanisms to reveal 'weak points'. Combinations of multiple targeting strategies with moderate compound concentrations are more promising and provoke less side-effects than highdose single treatment. Moreover, besides targeting the machinery directly involved in cell death execution, the preceding signaling pathways are attractive targets as these harbor critical upstream mediators with many of them understudied. Generally, redox signaling at the mitochondria is a vital pathway relevant to this concept in cancer research, as it controls both energy metabolism and regulation of cell death. Therefore, it is not surprising that mitochondrial dysfunction relates to a plethora of diseases and that many lead compounds are currently being developed in order to manipulate this organelle.2 Importantly, via generation of reactive oxygen species (ROS) or Ca...

By combining a Drosophila genome data base search and reverse transcriptase-PCR-based cDNA isolation, two G-protein-coupled receptors were cloned, which are the closest known invertebrate homologs of the mammalian opioid/somatostatin receptors. However, when functionally expressed in Xenopus oocytes by injection of Drosophila orphan receptor RNAs together with a coexpressed potassium channel, neither receptor was activated by known mammalian agonists. By applying a reverse pharmacological approach, the physiological ligands were isolated from peptide extracts from adult flies and larvae. Edman sequencing and mass spectrometry of the purified ligands revealed two decapentapeptides, which differ only by an N-terminal pyroglutamate/ glutamine. The peptides align to a hormone precursor sequence of the Drosophila genome data base and are almost identical to allatostatin C from Manduca sexta. Both receptors were activated by the synthetic peptides irrespective of the N-terminal modification. Sitedirected mutagenesis of a residue in transmembrane region 3 and the loop between transmembrane regions 6 and 7 affect ligand binding, as previously described for somatostatin receptors. The two receptor genes each containing three exons and transcribed in opposite directions are separated by 80 kb with no other genes predicted between. Localization of receptor transcripts identifies a role of the new transmitter system in visual information processing as well as endocrine regulation.Insect development and behavior are largely controlled by hormones and neurotransmitters often identified using a diverse array of bioassays. Besides the biogenic amines and the steroid-like hormones, insect hormones have been frequently classified as neuropeptides, which are widely distributed throughout the invertebrate kingdom (1, 2). Despite the large number of neuropeptides, the number of known cognate receptors in insects is still rather limited, with only a few examples in Drosophila that have been cloned based on homology with mammalian G-protein-coupled receptors (GPCRs) 1 (i.e. neuropeptide Y-like and tachykinin-like receptors) (3, 4). With the completion of the Drosophila genome project, a more thorough analysis of neuropeptide/receptor relations in insects is now possible. Whereas this genome data base allows the identification of peptide hormones previously isolated from other insect species as part of larger precursors (5), Drosophila GPCR-like sequences have been predicted mostly based on structural analogy of the transmembrane regions to mammalian neuropeptide receptor groups (6).Structural evidence for the existence of ligands identical or similar to their mammalian neuropeptide counterparts are lacking when searching the Drosophila genome data base. This may indicate that in insects these receptors are activated by an entirely different set of ligands. This view is supported by data reported here on the identification of two novel GPCRs from Drosophila melanogaster, termed Drostar1 and -2, which are structurally related to the mam...